# Chemotherapy Regimens

> **Evidence strength:**
> - Modified FOLFIRINOX — [Shroff et al., *JAMA Oncol.* 2019](https://pubmed.ncbi.nlm.nih.gov/31194228/) (Phase II cohort)
> - Gemcitabine + cisplatin ± durvalumab — [Oh et al., *NEJM* 2022 (TOPAZ-1)](https://pubmed.ncbi.nlm.nih.gov/35094080/)
> - FOLFOX second-line — [Lamarca et al., *Lancet Oncol.* 2021 (ABC-06)](https://pubmed.ncbi.nlm.nih.gov/33979517/)
> - CAPOX/FOLFOX adjuvant data extrapolated from [ESPAC-3](https://pubmed.ncbi.nlm.nih.gov/22382232/) and NCCN consensus

## Quick comparison table

| Regimen | Typical use | ORR / PFS / OS | Key toxicities | Older adult adjustments |
|---------|-------------|----------------|----------------|-------------------------|
| **Modified FOLFIRINOX** (oxaliplatin 85 mg/m², irinotecan 150 mg/m², infusional 5-FU 2400 mg/m²) | Fit patients, pancreatobiliary subtype | ORR 31–45%; median PFS 6.6 mo; OS 15 mo | Neutropenia, diarrhea, neuropathy, fatigue | Drop bolus 5-FU; start at 80% doses; G-CSF prophylaxis; check UGT1A1*28 |
| **Gemcitabine + cisplatin** | Standard for biliary tract; durable if bilirubin controlled | ORR 26%; OS 11.7 mo | Nephrotoxicity, tinnitus, fatigue | Use split-dose cisplatin (day 1 & 8, 25 mg/m²) or substitute carboplatin if CrCl <50 |
| **Gemcitabine + cisplatin + durvalumab** | TOPAZ-1 regimen; consider regardless of PD-L1 | OS 12.9 mo (HR 0.80) | Adds immune-related AEs (thyroiditis, hepatitis) | Monitor for autoimmune flares; treat-grade =2 toxicity with steroids |
| **Gemcitabine + nab-paclitaxel** | Alternative frontline for pancreatic-like biology | ORR 23%; OS 8.5–11 mo | Neuropathy, myelosuppression | Reduce nab-paclitaxel to 100 mg/m² when baseline neuropathy |
| **CAPOX / FOLFOX** | Adjuvant after R0/R1 or second-line metastatic | ABC-06: OS 6.2 vs 5.3 mo vs BSC | Neuropathy, mucositis | Capecitabine 1000 mg/m² bid days 1–14 q21d for age =75 |
| **NALIRI + 5-FU/LV (NAPOLI-style)** | Third line when oxaliplatin exhausted | Disease control ~35% | Diarrhea, fatigue | Start at 60–80% if bilirubin >ULN |
| **Capecitabine monotherapy** | Frail patients, maintenance, adjuvant intestinal subtype | Disease control 20–30% | Hand-foot syndrome, diarrhea | Use 1000 mg/m² bid or 1250 mg total BID with weekly labs |

## Regimen pearls

### Modified FOLFIRINOX

- **Why**: highest response among chemo options for pancreatobiliary histology; shrinks bulky nodes and improves biliary drainage chances.
- **Monitoring**: CBC weekly first cycle, CMP q2w, neuropathy check each visit, stool logs.
- **Dose-mod suggestions** (not prescriptions): start at 80% if =75 years, bilirubin 1–2× ULN, or ECOG 1–2; escalate if tolerated.
- **Questions to ask oncologist**
  - Will growth factor support be used up front?
  - How many cycles before restaging?
  - What is the plan if neuropathy appears (oxaliplatin stop-and-go)?

### Gemcitabine + cisplatin (± durvalumab)

- **Why**: standard for biliary tract, especially when neuropathy or irinotecan contraindicates FOLFIRINOX.
- **Practical tips**: hydrate aggressively; monitor Mg/K; check dental status prior to prolonged cisplatin.
- **Durvalumab** adds survival benefit regardless of PD-L1; watch for immune hepatitis in stented patients.
- **Questions**
  - Can cisplatin be split over two days to reduce nausea?
  - When will immune-related labs (TSH, cortisol) be checked?
  - What is the threshold for swapping to carboplatin?

### Gemcitabine + nab-paclitaxel

- **Evidence**: Extrapolated from metastatic pancreatic cancer (MPACT trial) and biliary phase II cohorts showing disease control ~50%.
- **Use case**: When cisplatin not tolerated or patient previously on FOLFOX.
- **Toxicity mitigation**: baseline neuropathy exam, weekly dose holds for grade 2 neuropathy.

### CAPOX / FOLFOX

- **Adjuvant**: NCCN recommends capecitabine x6 months post-Whipple; FOLFOX considered for R1 or node-positive disease.
- **Second-line**: ABC-06 proves modest OS benefit; combine with supportive care.
- **Elderly tips**: start capecitabine 1000 mg/m² bid; emphasize hand-foot prophylaxis (urea cream, vitamin B6 controversial but often used).

### Irinotecan-based (FOLFIRI, nal-IRI + 5-FU/LV)

- **Evidence**: Biliary phase II studies show response 10–15%; best for intestinal subtype or BRCA wild type when oxaliplatin exhausted.
- **Testing**: UGT1A1*28; adjust for hyperbilirubinemia.

### Capecitabine single-agent

- **Role**: Maintenance or when combination chemo intolerable.
- **Practical**: pair with pancreatic enzymes and loperamide instructions; schedule telehealth toxicity reviews.

## Liver-directed therapy interplay

Systemic therapy should start before or alongside SBRT/Y-90. Hold chemotherapy 1 week before SBRT and resume 1–2 weeks after if bilirubin stable.

## Supportive bundles during chemo

- **Enzyme replacement** (pancrelipase 25,000–40,000 units with meals) reduces steatorrhea.[3](https://www.nccn.org/guidelines)
- **Antipruritic regimen**: cholestyramine + hydroxyzine + topical menthol for stent-related itching.
- **Vaccinations**: influenza annually, pneumococcal as per CDC, COVID booster.

Refer to [Targeted & Immunotherapy](targeted-immunotherapy.md) for biomarker-driven options.
